Saturday, Jan 20 2018 | Time 22:20 Hrs(IST)
image
  • Restrictions in parts of Srinagar
  • Russia concerned by Turkish military operation in Syria, calls for restraint
  • Ex-gratia relief for civilians killed in border firing enhanced to Rs 5 lakh: J&K DyCM
  • Forward areas of 5 districts affected by sudden spurt in cross-border firing: J&K Govt
  • Cine stars, Ex MLA and hundreds of BJD and Congress workers join BJP
  • Centre confident of doubling farmers` income by 2022: Radha Mohan
  • Odisha’s export turnover to reach Rs 1 lakh crore by 2025: Samal
  • CM Biren calls for egalitarian society
  • More than 4 crores people to participate in Human Chain in Bihar tomorrow
  • Punjab selected for national award for immense use IT during polls
  • Nine die in plastic factory fire in Bawana Delhi
  • East Bengal get ready to host arch-rivals Mohun Bagan in return I-League Kolkata derby
  • Joint action plan for coastal area security: Collector
  • Philippine troops fight first clash with militants since Marawi battle, six wounded
  • Illegal construction in Shimla: JAC to convene meeting to chalk out strategy for remedial
Science Technology Share

Circassia gives up on allergy after house dust mite study fails"

Circassia gives up on allergy after house dust mite study fails"

LONDON, Apr 18 (Reuters) Britain's Circassia Pharmaceuticals is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader respiratory business.The failure of the company's immunotherapy to perform better than placebo in fighting dust mite allergy in a Phase IIb test follows similar negative results in a Phase III trial against cat allergy last year. The company's stock lost two-third's of its value in a single session on the June 2016 cat results, which many investors feared undermined the allergy thesis, and the reaction on Tuesday was more muted, with shares losing around 3 percent. In both cases, the company said, the immunotherapy failed because of a marked placebo effect among patients not on therapy. The top shareholders in Circassia, which listed on the London stock market in March 2014 in Britain's largest biotech flotation for decades, are Invesco and Neil Woodford's investment management company, both big backers of UK science. Woodford suffered another setback earlier this month when Allied Minds, which commercialises ideas from universities, announced a large writedown. Circassia Chief Executive Steve Harris said he was "naturally disappointed" by the dust mite study failure. "We remain convinced that the technology has biologic activity, but we also believe the difficulty in overcoming the placebo effect using the field study designs required by regulators represents a significant hurdle, and consequently we will make no further investment in our allergy portfolio," he said. Instead, Circassia will concentrate on its wider respiratory business, in particular a new U.S. commercial collaboration with AstraZeneca. Circassia last month secured U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease for up to $230 million. REUTERS RJ

More News
Middle East respiratory syndrome, a viral respiratory disease

Middle East respiratory syndrome, a viral respiratory disease

19 Jan 2018 | 1:30 PM

Kolkata, Jan 19 (UNI) Middle East respiratory syndrome (MERS) is a viral respiratory disease
caused by a novel coronavirus (Middle East respiratory syndrome coronavirus, or MERS‐CoV)
that was first identified in Saudi Arabia in 2012.

 Sharesee more..

Science has to be people centric: Dr Harsh Vardhan

18 Jan 2018 | 1:08 PM

Hyderabad, Jan 18 (UNI) Union Minister for Science and Technology Harsh Vardhan has said that the Science has to be people centric and its benefits would deliver to the people.

 Sharesee more..
Greater efforts needed to meet international family planning goals

Greater efforts needed to meet international family planning goals

17 Jan 2018 | 12:32 PM

Kolkata, Jan 17 (UNI) Women and girls have a human right to choose whether and when to become pregnant.

 Sharesee more..
TN pioneer in organ transplants, other states should follow it : Venkaiah

TN pioneer in organ transplants, other states should follow it : Venkaiah

16 Jan 2018 | 5:13 PM

Chennai, Jan 16 (UNI) Observing that Tamil Nadu was a pioneering state in organ transplantation in the country, Vice President M Venkaiah Naidu on Tuesday said other states should emulate it in providing affording medical care to the people.

 Sharesee more..
Echinococcosis, a parasitic disease that occurs in two main forms in humans

Echinococcosis, a parasitic disease that occurs in two main forms in humans

13 Jan 2018 | 12:16 PM

Kolkata, Jan 13 (UNI) Echinococcosis is a parasitic disease that occurs in two main forms in humans: cystic echinococcosis (also known as hydatidosis) and alveolar echinococcosis, caused by the tapeworms Echinococcus granulosus and Echinococcus multilocularis, respectively.

 Sharesee more..
image